Objectives The METIMMOX 1 and 2 projects, led by Akershus University Hospital (AUH), constitute a pioneering clinical study investigating inoperable, metastatic, microsatellite-stable colorectal cancer. The study aimed to evaluate the efficacy, safety, and tolerability of sequentially adding immune-modulating therapy to standard chemotherapy. In collaboration with Oslo University Hospital, the project generated extensive and complex mass cytometry datasets to identify biomark

Objectives The OxyTarget clinical trial was conducted at Akershus University Hospital (AUH). This study attempted to establish a reliable method for detection of rectal cancer patients with aggressive tumors at risk of metastatic disease and death using an experimental functional MRI procedure. Blood samples were collected from 36 patients before undergoing neoadjuvant chemoradiotherapy and, eventually, surgery. Oslo University Hospital (OUH) performed mass cytometry experime

Illustration by Sebastian Franco Ulloa. Cytofit started with a concrete problem: cancer immunotherapy researchers analyzing patient cell samples with mass cytometry(CyTOF) were generating rich and complex datasets, but turning those data into insights was time-consuming, fragmented, and technically demanding. Traditional analysis workflows relied on a patchwork of complicated software tools, scripts, manual gating and subjective decision making. Time from data availability to